Scancell Share Discussion Threads

[inanaco] 04/12/2024 14:27

wake up call ..................

[inanaco] 04/12/2024 14:27

A Russian ship fired “signal munitions” near a German military helicopter in the Baltic Sea, the German foreign minister has revealed

Annalena Baerbock mentioned the incident on the sidelines of a meeting of Nato foreign ministers in Brussels, but did not provide any details or information as to when the incident occurred.

German media has reported that the helicopter was undertaking a reconnaissance mission.

It is not clear if the Russian ship fired directly at the helicopter or what kind of “signal munition” was used. Ships commonly carry signal flares to use in emergency situations.

Ms Baerbock added that ships bypassing sanctions related to Russia’s war in Ukraine frequently transit through the Baltic Sea.

She also announced that Baltic Sea patrols would be increased to monitor pipelines and data cables after several acts of suspected Russian sabotage.

The German foreign minister on Tuesday suggested that German troops could be sent to Ukraine to enforce a future ceasefire between Kyiv and Moscow, although chancellor Olaf Scholz on Wednesday said the idea was “out of the question” for him.

[inanaco] 04/12/2024 14:23

any tax ? like CGT or PAYE .... do you actually have a job ?

[inanaco] 04/12/2024 14:21

Corporation tax ?

[inanaco] 04/12/2024 14:12

do you pay VAT 2tyke ?

[2tyke] 04/12/2024 14:11

Surely surely the giggle for today......'inane understands money' 😂 😂 😂

[inanaco] 04/12/2024 13:59

Ivy ... i don't work in the industry ... at all

but what i do understand is money ! ...

your experience in this field is so good you predicted MTFB and a Billion Dollar HVO

you also sold me your shares here at 8p

open up your account to scrutiny ... before you claim yourself as an EXPERT

as your first entry into scancell was at 27p

mine was at 6p ...

ATB

[torquayfan] 04/12/2024 13:55

Bermuda 15007 thanks.

With respect,"It's not easy to exit from such a large position". I'm not sure why that would be so. Depends what precisely, is on offer . . .

I don't think Nigel has made a 'fair point' as you say. Surely Scancell is still small beer for Redmile and if you think they're daft enough to grab $120 million profit when much more might be around the corner, well I disagree. IMHO I'd guess they are much sharper than that.

I agree with you that an offer from Genmab, (maybe $500 million), for the Glymabs platform alone, would be very hard for Redmile to resist.

But I think we shall see that Redmile have more 'balls' than to 'cut and run', as if they couldn't perceive the wider and total picture.

[inanaco] 04/12/2024 13:51

Konars Post on the LSE is NOT accurate .............



Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash
Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms
COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).

With the completion of this strategic transaction, we are excited to welcome our new colleagues and their expertise in developing next-generation antibody-drug conjugates to our exceptionally talented R&D team,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genmab. “We look forward to unlocking new opportunities as we strengthen our oncology portfolio and continue to work towards our goal of transforming the lives of patients with innovative antibody medicines.”

The acquisition gives Genmab worldwide rights to ProfoundBio’s portfolio of next-generation ADCs, further broadening and strengthening its clinical pipeline. These programs include Rina-S, a potential best-in-class, clinical-stage, FRα-targeted, Topo1 ADC, currently in part 2 of a Phase 1/2 clinical trial, for the treatment of ovarian cancer and other FRα-expressing solid tumors. The addition of Rina-S to Genmab’s portfolio enables Genmab to deepen its presence in the gynecologic oncology space and establish a firm foundation in solid tumors. Based on the data from the ongoing Phase 1/2 clinical trial, which also indicates that Rina-S has the potential to address a broader patient population than first-generation FRα-targeted ADCs, Genmab intends to broaden the development plans for Rina-S within ovarian cancer and other FRα-expressing solid tumors. In January 2024, the U.S. Food and Drug Administration (U.S. FDA) granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

In addition, the transaction provides Genmab with access to ProfoundBio’s novel ADC technology platforms, which complement Genmab’s already validated suite of proprietary technology platforms. The combination of the companies’ technology platforms could create new opportunities to generate and develop new medicines with the potential to transform the treatment of cancer and improve patients’ lives.

As previously disclosed in Company Announcement No. 26, following the closing of this acquisition, Genmab’s operating expenses, before expenses incurred by it in connection with the transaction, are anticipated to be at or moderately above the upper end of the previously disclosed guidance range of DKK 12.4 -13.4 billion. The anticipated increase reflects the incremental R&D investment to support the advancement of ProfoundBio’s clinical programs, primarily Rina-S. Genmab’s revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 – 20.5 billion. Genmab expects to update its guidance no later than in connection with its second quarter 2024 earnings.

[ivyspivey] 04/12/2024 13:49

Nana your below comment exposes your total lack of experience in the industry

Scancell is a strategic fit for Genmab in fact any Big Pharma ...

Pharmas spend up to 10-15 years determining and refining their strategic focus constantly and have a clear vision and pathway at least 10 years ahead.They do not change that and make major strategic decisions like deciding to buy the likes of SCLP based on however great the potential is of it does not fit in with their plan.
There will be pharma where SCLP will fit in or certainly the cancer Vax bit and I can see the rationale for Genmab having net rest in buying the Glycan platform.
But they will have no interest via the rest of SCLP but why do you just not accept that you can be wrong.

[inanaco] 04/12/2024 13:44

i guess Loggie ... has weighed in the aluminium from the 30 year collection of tinnies ...flat packed and stacked


04-Dec-24 12:16:24 14.15 325,000 Unknown* 13.50 14.50 45.99k

[inanaco] 04/12/2024 13:37

"unique methodology"

ATB

[inanaco] 04/12/2024 13:34

the value is in this statement


""""Scancell is building a pipeline of differentiated anti-cancer monoclonal antibodies ('mAbs') that target sugar motifs rather than proteins. The Company currently has five novel mAbs in early-stage development and has the potential to use its unique methodology to identify many more mAbs against glycan targets in the future""""

[inanaco] 04/12/2024 13:22

what for ? Scancell in the RNS confirms this was the exclusive deal

Following on from a period of exclusive evaluation announced in June 2024, Genmab has exercised its option to license an anti-glycan monoclonal antibody generated via Scancell's proprietary

GlyMab® platform

You have to appreciate under the NDA scancell had to in effect, create a phantom customer

[chilltime] 04/12/2024 13:10

Agreed Bermuda I recall a very clear comment about it being a different company.

I’ll see if I can find the interview comment, to clarify the point.

[2tyke] 04/12/2024 12:18

How are you even getting signal on the moon inane ?
NASDAQ..lol
The last couple of uk biotech companies that I saw listed on NASDAQ...the share price dropped BIG.
As always...the market is a place of irony...and complete contradiction.

[inanaco] 04/12/2024 11:06

The glymab trials will behave like Scib1 double check point ... Data will come in very fast giving us a pretty good picture when they release data, I suspect Genmab will be in a position to use that insider information to take on more of the pipeline exactly as they have done with this exclusive period.

[inanaco] 04/12/2024 10:58

Scancell is a strategic fit for Genmab in fact any Big Pharma ...

its a simple strategy of not breaking it up ! It has the scientific development capacity already developed to take products to clinic ready and beyond

you cannot argue it cannot operate as a standalone .. it already has that track record

it also has a pipeline that is near to registrational trials

what is missing is the Cash to really drive it forward, Calculus Exit does not help unless you are smart enough to buy with the knowledge that the industry is committing to the science and the data coming from the trials is highly valued.

Big pharma problem is to much money trying to find the ""right home""

we are in the position that no party can make a hostile bid

Redmile are not in this to make £120m ... they would not take a seat on the board if it was a flip and with $1.2b of potential sales already in the pipeline it would not make financial sense considering they got involved because of immunobody and moditope .. which we have only received snippets of.

Genmab have doubled down on the investment towards the platform so we can be pretty sure they are going ahead with the first Glymab, which means we don't run out of cash next year !!

[marcusl2] 04/12/2024 10:56

We would possibly be better on Nasdaq. The end game is probably a takeover. Maybe when Modi-1 with doublet and iScib results come in.

[the skipper] 04/12/2024 10:34

I think this is the link you meant to post Marcus:

Frankly I’m amazed at the market’s poor reaction to this deal. Maybe it’s because the amount of cash up front hasn’t been clarified.

[2tyke] 04/12/2024 09:38

Yep Sp's carry on carving out their sentiment patterns. If they're heading lower...they continue lower.
As always external events are just 'spun' according to the price reaction.....in hindsight of course !

[bermudashorts] 04/12/2024 09:23

Chilltime,

Agree - when the exclusivity deal was first announced I remember posting that I wondered whether it was with Genmab because Lindy had previously mentioned that they were interested in a second mAb. However, later in an interview she seemed to suggest that it was with a different company, but it is defintiely this deal and the same mAb.

[chilltime] 04/12/2024 09:20

Bermuda

I only had chance of a brief read before posting. I see your point, which seems to be at odds with what was said mid year on the exclusivity point, if I recall it correctly.

Busy at the moment, I’ll check the facts this morning and report back later.

The point being I believe lindy said the exclusive deal Glymab was with another company besides Genmab